Cargando…

Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response

OBJECTIVE: S100B is a neurotrophic factor that is involved in neuroplasticity. Neuroplasticity is disrupted in depression; however, treatment with antidepressants can restore neuroplasticity. S100B has previously been used as a biological marker for neuropathology and neuroplasticity; therefore, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Byong-Su, Kim, Hyeran, Lim, Shinn-Won, Jang, Ki-Won, Kim, Doh-Kwan
Formato: Texto
Lenguaje:English
Publicado: Korean Neuropsychiatric Association 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796025/
https://www.ncbi.nlm.nih.gov/pubmed/20046365
http://dx.doi.org/10.4306/pi.2008.5.3.193
_version_ 1782175495332298752
author Jang, Byong-Su
Kim, Hyeran
Lim, Shinn-Won
Jang, Ki-Won
Kim, Doh-Kwan
author_facet Jang, Byong-Su
Kim, Hyeran
Lim, Shinn-Won
Jang, Ki-Won
Kim, Doh-Kwan
author_sort Jang, Byong-Su
collection PubMed
description OBJECTIVE: S100B is a neurotrophic factor that is involved in neuroplasticity. Neuroplasticity is disrupted in depression; however, treatment with antidepressants can restore neuroplasticity. S100B has previously been used as a biological marker for neuropathology and neuroplasticity; therefore, in this study, we compared serum S100B levels in depressive patients to those of normal controls. In addition, we compared the serum S100B levels of antidepressant responders to those of nonresponders. METHODS: Thirty five normal controls and 59 depressive patients were enrolled in this study. Depressive patients entered a 6 week clinical trial that included treatment with antidepressants. The serum S100B levels and clinical assessments, which included Hamilton depression rating scores, were measured at baseline and after 6 weeks of treatment with antidepressants. The difference in the serum S100B levels between depressive patients and normal controls and between antidepressant responders and nonresponders was then compared. RESULTS: There were no significant differences in the serum S100B levels of normal controls and depressive patients. In addition, 30 of the depressive patients responded to antidepressant treatment while 29 did not. Finally, the responders had significantly higher baseline serum S100B levels than the nonresponders. CONCLUSION: The results of this study suggest that the baseline serum S100B level is associated with the subsequent response to antidepressants. In addition, the high baseline serum S100B level that was observed in depressive patients may enhance neuroplasticity, which results in a favorable therapeutic response to antidepressants.
format Text
id pubmed-2796025
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Korean Neuropsychiatric Association
record_format MEDLINE/PubMed
spelling pubmed-27960252009-12-30 Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response Jang, Byong-Su Kim, Hyeran Lim, Shinn-Won Jang, Ki-Won Kim, Doh-Kwan Psychiatry Investig Original Article OBJECTIVE: S100B is a neurotrophic factor that is involved in neuroplasticity. Neuroplasticity is disrupted in depression; however, treatment with antidepressants can restore neuroplasticity. S100B has previously been used as a biological marker for neuropathology and neuroplasticity; therefore, in this study, we compared serum S100B levels in depressive patients to those of normal controls. In addition, we compared the serum S100B levels of antidepressant responders to those of nonresponders. METHODS: Thirty five normal controls and 59 depressive patients were enrolled in this study. Depressive patients entered a 6 week clinical trial that included treatment with antidepressants. The serum S100B levels and clinical assessments, which included Hamilton depression rating scores, were measured at baseline and after 6 weeks of treatment with antidepressants. The difference in the serum S100B levels between depressive patients and normal controls and between antidepressant responders and nonresponders was then compared. RESULTS: There were no significant differences in the serum S100B levels of normal controls and depressive patients. In addition, 30 of the depressive patients responded to antidepressant treatment while 29 did not. Finally, the responders had significantly higher baseline serum S100B levels than the nonresponders. CONCLUSION: The results of this study suggest that the baseline serum S100B level is associated with the subsequent response to antidepressants. In addition, the high baseline serum S100B level that was observed in depressive patients may enhance neuroplasticity, which results in a favorable therapeutic response to antidepressants. Korean Neuropsychiatric Association 2008-09 2008-09-30 /pmc/articles/PMC2796025/ /pubmed/20046365 http://dx.doi.org/10.4306/pi.2008.5.3.193 Text en Copyright © 2008 Official Journal of Korean Neuropsychiatric Association http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jang, Byong-Su
Kim, Hyeran
Lim, Shinn-Won
Jang, Ki-Won
Kim, Doh-Kwan
Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response
title Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response
title_full Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response
title_fullStr Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response
title_full_unstemmed Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response
title_short Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response
title_sort serum s100b levels and major depressive disorder: its characteristics and role in antidepressant response
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796025/
https://www.ncbi.nlm.nih.gov/pubmed/20046365
http://dx.doi.org/10.4306/pi.2008.5.3.193
work_keys_str_mv AT jangbyongsu serums100blevelsandmajordepressivedisorderitscharacteristicsandroleinantidepressantresponse
AT kimhyeran serums100blevelsandmajordepressivedisorderitscharacteristicsandroleinantidepressantresponse
AT limshinnwon serums100blevelsandmajordepressivedisorderitscharacteristicsandroleinantidepressantresponse
AT jangkiwon serums100blevelsandmajordepressivedisorderitscharacteristicsandroleinantidepressantresponse
AT kimdohkwan serums100blevelsandmajordepressivedisorderitscharacteristicsandroleinantidepressantresponse